Kiora Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
KPRX Nasdaq 2834 www.kiorapharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Kiora Pharmaceuticals, Inc.

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema - Feb 11th, 2025 11:45 am
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Nov 15th, 2024 11:06 am
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Nov 8th, 2024 12:00 pm
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial - Oct 30th, 2024 11:28 am
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa - Oct 29th, 2024 10:45 am
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - Sep 25th, 2024 1:55 pm
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies - Aug 9th, 2024 11:00 am
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies - Jul 30th, 2024 10:45 am
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation - Jul 10th, 2024 11:00 am
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors - Jul 1st, 2024 10:54 am
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board - Jun 25th, 2024 10:45 am
Is Kiora Pharmaceuticals (KPRX) Stock Undervalued Right Now? - Jun 18th, 2024 1:40 pm
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) stock most popular amongst retail investors who own 39%, while hedge funds hold 31% - Jun 11th, 2024 12:04 pm
Lytham Partners Spring 2024 Investor Conference Starts Tomorrow, May 30, 2024 - May 29th, 2024 10:44 pm
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease - May 10th, 2024 11:00 am
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference - May 8th, 2024 11:00 am
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa - May 6th, 2024 11:00 am
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study - Apr 11th, 2024 11:00 am
Kiora Pharmaceuticals to Present at Upcoming Investor Conferences - Apr 5th, 2024 11:00 am
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting - Mar 28th, 2024 10:45 am